Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease

F. Nagy, T. Molnár, Zoltán Szepes, Klaudia Farkas, T. Nyári, J. Lonovics

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. Methods: Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively. The 6-MP doses were gradually increased from 0.5 up to 1.0-1.5 mg/kg per day. Clinical activity indicies (CDAI/CAI), laboratory variables and daily doses of oral 5-ASA, corticosteroids, and 6-MP were assessed before and in the first, sixth and twelfth months of treatment. Results: In 9 patients, 6-MP was withdrawn in the first 2 wk due to an early hypersensitivity reaction. Medication was ineffective within 6 mo in 6 CD patients, and myelotoxic reaction was observed in two. Data were evaluated at the end of the sixth month in 12 (8 UC, 4 CD) patients, and after the first year in 9 (6 UC, 3 CD) patients. CDAI decreased transiently at the end of the sixth month, but no significant changes were observed in the CDAI or the CAI values at the end of the year. Leukocyte counts (P = 0.01), CRP (P = 0.02), and serum iron (P = 0.05) values indicated decreased inflammatory reactions, especially in the UC patients at the end of the year, making the possibility to taper oral steroid doses. Conclusion: About one-third of the previously AZA-intolerant patients showed adverse effects on taking 6MP. In our series, 20 patients tolerated 6MP, but it was ineffective in 8 CD cases, and valuable mainly in ulcerative colitis patients.

Original languageEnglish
Pages (from-to)4342-4346
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number27
DOIs
Publication statusPublished - Jul 21 2008

Fingerprint

6-Mercaptopurine
Azathioprine
Inflammatory Bowel Diseases
Hypersensitivity
Ulcerative Colitis
Crohn Disease
Therapeutics
Leukocyte Count
Adrenal Cortex Hormones
Iron
Steroids

Keywords

  • 6-mercaptopurine
  • Azathioprine
  • Efficacy
  • Inflammatory bowel disease
  • Side effects

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. / Nagy, F.; Molnár, T.; Szepes, Zoltán; Farkas, Klaudia; Nyári, T.; Lonovics, J.

In: World Journal of Gastroenterology, Vol. 14, No. 27, 21.07.2008, p. 4342-4346.

Research output: Contribution to journalArticle

@article{04ee483451fe4aeeb0ea3c560ad9a552,
title = "Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease",
abstract = "Aim: To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. Methods: Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively. The 6-MP doses were gradually increased from 0.5 up to 1.0-1.5 mg/kg per day. Clinical activity indicies (CDAI/CAI), laboratory variables and daily doses of oral 5-ASA, corticosteroids, and 6-MP were assessed before and in the first, sixth and twelfth months of treatment. Results: In 9 patients, 6-MP was withdrawn in the first 2 wk due to an early hypersensitivity reaction. Medication was ineffective within 6 mo in 6 CD patients, and myelotoxic reaction was observed in two. Data were evaluated at the end of the sixth month in 12 (8 UC, 4 CD) patients, and after the first year in 9 (6 UC, 3 CD) patients. CDAI decreased transiently at the end of the sixth month, but no significant changes were observed in the CDAI or the CAI values at the end of the year. Leukocyte counts (P = 0.01), CRP (P = 0.02), and serum iron (P = 0.05) values indicated decreased inflammatory reactions, especially in the UC patients at the end of the year, making the possibility to taper oral steroid doses. Conclusion: About one-third of the previously AZA-intolerant patients showed adverse effects on taking 6MP. In our series, 20 patients tolerated 6MP, but it was ineffective in 8 CD cases, and valuable mainly in ulcerative colitis patients.",
keywords = "6-mercaptopurine, Azathioprine, Efficacy, Inflammatory bowel disease, Side effects",
author = "F. Nagy and T. Moln{\'a}r and Zolt{\'a}n Szepes and Klaudia Farkas and T. Ny{\'a}ri and J. Lonovics",
year = "2008",
month = "7",
day = "21",
doi = "10.3748/wjg.14.4342",
language = "English",
volume = "14",
pages = "4342--4346",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "27",

}

TY - JOUR

T1 - Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease

AU - Nagy, F.

AU - Molnár, T.

AU - Szepes, Zoltán

AU - Farkas, Klaudia

AU - Nyári, T.

AU - Lonovics, J.

PY - 2008/7/21

Y1 - 2008/7/21

N2 - Aim: To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. Methods: Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively. The 6-MP doses were gradually increased from 0.5 up to 1.0-1.5 mg/kg per day. Clinical activity indicies (CDAI/CAI), laboratory variables and daily doses of oral 5-ASA, corticosteroids, and 6-MP were assessed before and in the first, sixth and twelfth months of treatment. Results: In 9 patients, 6-MP was withdrawn in the first 2 wk due to an early hypersensitivity reaction. Medication was ineffective within 6 mo in 6 CD patients, and myelotoxic reaction was observed in two. Data were evaluated at the end of the sixth month in 12 (8 UC, 4 CD) patients, and after the first year in 9 (6 UC, 3 CD) patients. CDAI decreased transiently at the end of the sixth month, but no significant changes were observed in the CDAI or the CAI values at the end of the year. Leukocyte counts (P = 0.01), CRP (P = 0.02), and serum iron (P = 0.05) values indicated decreased inflammatory reactions, especially in the UC patients at the end of the year, making the possibility to taper oral steroid doses. Conclusion: About one-third of the previously AZA-intolerant patients showed adverse effects on taking 6MP. In our series, 20 patients tolerated 6MP, but it was ineffective in 8 CD cases, and valuable mainly in ulcerative colitis patients.

AB - Aim: To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. Methods: Twenty nine previously confirmed Crohn's disease (CD) (n = 14) and ulcerative colitis (UC) (n = 15) patients with a known previous (AZA) hypersensitivity reaction were studied prospectively. The 6-MP doses were gradually increased from 0.5 up to 1.0-1.5 mg/kg per day. Clinical activity indicies (CDAI/CAI), laboratory variables and daily doses of oral 5-ASA, corticosteroids, and 6-MP were assessed before and in the first, sixth and twelfth months of treatment. Results: In 9 patients, 6-MP was withdrawn in the first 2 wk due to an early hypersensitivity reaction. Medication was ineffective within 6 mo in 6 CD patients, and myelotoxic reaction was observed in two. Data were evaluated at the end of the sixth month in 12 (8 UC, 4 CD) patients, and after the first year in 9 (6 UC, 3 CD) patients. CDAI decreased transiently at the end of the sixth month, but no significant changes were observed in the CDAI or the CAI values at the end of the year. Leukocyte counts (P = 0.01), CRP (P = 0.02), and serum iron (P = 0.05) values indicated decreased inflammatory reactions, especially in the UC patients at the end of the year, making the possibility to taper oral steroid doses. Conclusion: About one-third of the previously AZA-intolerant patients showed adverse effects on taking 6MP. In our series, 20 patients tolerated 6MP, but it was ineffective in 8 CD cases, and valuable mainly in ulcerative colitis patients.

KW - 6-mercaptopurine

KW - Azathioprine

KW - Efficacy

KW - Inflammatory bowel disease

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=55949090947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949090947&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.4342

DO - 10.3748/wjg.14.4342

M3 - Article

C2 - 18666323

AN - SCOPUS:55949090947

VL - 14

SP - 4342

EP - 4346

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 27

ER -